Table 3.

mdNLR and mortality^a for small cell lung cancer cases by subgroup

Variable	Strata definition	Lung cancer-specific mortality			All-cause mortality
		Death	Case	HR (95% CI)	Death	Case	HR (95% CI)
		N	N		N	N
Age at blood drawb	< 64.1 years	38	39	1.21 (0.96, 1.52)	38	39	1.21 (0.96, 1.52)
	≥ 64.1 years	39	42	1.22 (0.77, 1.95)	42	42	1.21 (0.77, 1.91)
	Interaction Pc	0.88			0.98
Intervention arm	Active	41	43	1.17 (0.85, 1.60)	42	43	1.17 (0.85, 1.60)
	Placebo	36	38	1.86 (1.29, 2.69)	38	38	1.74 (1.24, 2.42)
	Interaction Pc	0.64			0.71
Sex	Female	31	33	1.09 (0.85, 1.41)	33	33	1.10 (0.86, 1.42)
	Male	46	48	1.46 (1.07, 1.98)	47	48	1.49 (1.10, 2.02)
	Interaction Pc	0.55			0.44
Smoking history at blood drawb	< 59.3 pack years	41	44	1.12 (0.86, 1.46)	44	44	1.14 (0.88, 1.48)
	≥ 59.3 pack years	36	37	1.28 (0.97, 1.70)	36	37	1.28 (0.97, 1.70)
	Interaction Pc	0.60			0.45
Smoking status at blood draw	Former	28	30	1.14 (0.83, 1.56)	29	30	1.12 (0.83, 1.51)
	Current	49	51	2.00 (1.32, 3.03)	51	51	1.96 (1.30, 2.96)
	Interaction Pc	0.03			0.03
Time between blood draw and diagnosisb	< 4.5 years	39	41	1.35 (0.95, 1.91)	40	41	1.34 (0.95, 1.89)
	≥ 4.5 years	38	40	1.20 (0.93, 1.54)	40	40	1.16 (0.91, 1.49)
	Interaction Pc	0.76			0.68

CI Confidence Interval, HR Hazard Ratio, mdNLR methylation-derived neutrophil-to-lymphocyte ratio

^aMortality was estimated using Cox proportional hazards models adjusted for age, sex, smoking status, pack years at blood draw, and time between blood draw and diagnosis; stage (early (I/II), late (III/IV), unknown) was included as a strata variable

^bMean values among SCLC cases used to define strata

^cInteraction P-value for the product term between continuous mdNLR and the dichotomized covariate; for intervention arm, both the main-effect and interaction terms were added to calculate the interaction P since intervention arm was not included in the final, fully adjusted models